Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) posted its quarterly earnings results on Tuesday. The medical device company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02), Zacks reports. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The business had revenue of $27.94 million for the quarter. Xtant Medical updated its FY 2024 guidance to EPS.
Xtant Medical Stock Down 4.0 %
NYSEAMERICAN:XTNT traded down $0.02 on Friday, reaching $0.43. The company’s stock had a trading volume of 29,862 shares, compared to its average volume of 101,573. Xtant Medical has a 1-year low of $0.43 and a 1-year high of $1.45. The company has a current ratio of 2.12, a quick ratio of 1.01 and a debt-to-equity ratio of 0.42. The stock has a market cap of $59.90 million, a price-to-earnings ratio of -3.31 and a beta of 0.39.
Analysts Set New Price Targets
Separately, Craig Hallum set a $1.50 price objective on Xtant Medical and gave the company a “buy” rating in a report on Friday, October 18th.
About Xtant Medical
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
- Five stocks we like better than Xtant Medical
- Best Stocks Under $10.00
- Top-Performing Non-Leveraged ETFs This Year
- Quiet Period Expirations Explained
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- What are earnings reports?
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
